Advertisement

Immunologic Research

, Volume 50, Issue 2–3, pp 159–174 | Cite as

Role of TNF superfamily ligands in innate immunity

  • Nikola L. VujanovicEmail author
UNIVERSITY OF PITTSBURGH IMMUNOLOGY 2011

Abstract

Natural killer (NK) cells and dendritic cells (DCs) are essential effector cells of the innate immune system that rapidly recognize and eliminate microbial pathogens and abnormal cells, and induce and regulate adaptive immune functions. While NK cells express perforin and granzymes in the lysosomal granules and transmembrane tumor necrosis factor superfamily ligands (tmTNFSFL) on the plasma membrane, DCs express only tmTNFSFL on the plasma membrane. Perforin and granzymes are cytolytic molecules, which NK cells use to mediate a secretory/necrotic killing mechanism against rare leukemia cell targets. TNFSFL are pleiotropic transmembrane molecules, which can mediate a variety of important functions such as apoptosis, development of peripheral lymphoid tissues, inflammation and regulation of immune functions. Using tmTNFSFL, NK cells and DCs mediate a cell contact-dependent non-secretory apoptotic cytotoxic mechanism against virtually all types of cancer cells, and cross talk that leads to polarization and reciprocal stimulation and amplification of Th1 type cytokines secreted by NK cells and DCs. In this paper, we review and discuss the supporting evidence of the non-secretory, tmTNFSFL-mediated innate mechanisms of NK cells and DCs, their roles in anticancer immune defense and potential of their modulation and use in prevention and treatment of cancer.

Keywords

TNF superfamily ligands TNF superfamily receptors NK cells Dendritic cells Cytotoxicity Cross talk 

Notes

Acknowledgments

I am grateful to the following previous and current members of my laboratory for their contributions in the presented studies: Bratislav Janjic, Ganwei Lu, Jelena Janjic, Alexei Pimenov and Dejan Baskic (studies of NK cell and DC apoptotic tumoricidal activity); Jun Xu, Valeria Makarenkova, Petar Popovic, Jennifer Liberatore-Tan, Lisheng Ge, Ayan Chakrabarti, Michael Magee, Andrea Sobo-Vujanovic, Toshie Yoneyama and Sebnem Unlu (studies of NK cell/DC cross talk). I am also indebted to the following collaborators: Lazar Vujanovic, Lisa Butterfield, Sigeki Nagashima, Roberto Giorda, Theresa Whiteside, Ronald Herberman, Simon Watkins, Nebojsa Arsenijevic, Per Basse, Eugene Myers, Susan Gollin, Jennifer Hunt and Walter Storkus. In addition, I am obliged to David Szymkowski (XENCOR, Monrovia, CA) who has generously provided us with dominant negative TNF (DN-TNF, XPro1595 and XENP550) reagents. This study was supported by research funding from the National Institute of Health grants I-PO DE13059, RO1 DE14775, RO1 DE17150 and the University of Pittsburgh Cancer Institute and the Henry L. Hillman Foundation to N.L.V.

References

  1. 1.
    Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death. Genes Dev. 1998;12:2821–30.PubMedGoogle Scholar
  2. 2.
    Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994;264:667–8.PubMedGoogle Scholar
  3. 3.
    Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461–5.PubMedGoogle Scholar
  4. 4.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959–69.PubMedGoogle Scholar
  5. 5.
    Vujanovic NL. Role of TNF family ligands in antitumor activity of natural killer cells. Internat Rev Immunol. 2001;20:415–35.Google Scholar
  6. 6.
    Vujanovic NL, Nagashima S, Herberman RB, et al. Cytotoxic mechanisms of natural killer cells. In: Lukic M, Dujic A, Cuperlovic K, editors. Immunoregulation in health and disease-experimental and clinical aspects. New York: Acad Press; 1997. p. 349–67.Google Scholar
  7. 7.
    Green DR, Droin N, Pinkoski M. Activation induced cell death in T cells. Immunol Rev. 2003;193:70–81.PubMedGoogle Scholar
  8. 8.
    Demeter J, Ramisch S, et al. Polymorphism of the tumor necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukemia. Brit J Hematol. 1997;97:107–12.Google Scholar
  9. 9.
    Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643–9.PubMedGoogle Scholar
  10. 10.
    Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmocytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med. 1998;187:1825–38.PubMedGoogle Scholar
  11. 11.
    Landowski TH, Ou N, Buyksal I, et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997;90:4266–70.PubMedGoogle Scholar
  12. 12.
    Smyth MJ, Kelly JM, Baxter AG, et al. An essential role of tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med. 1998;188:1611–9.PubMedGoogle Scholar
  13. 13.
    Ito D, Back TC, Shakhov AN, et al. Mice with a targeted mutation in lymphotoxin-α exhibit enhanced tumor growth and metastases: Impaired NK cell development and recruitment. J Immunol. 1999;163:2809–15.PubMedGoogle Scholar
  14. 14.
    Hayward AR, Levy J, Facchetii F, et al. Cholangiopathy and tumors of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol. 1997;158:977–83.PubMedGoogle Scholar
  15. 15.
    Ostenstand B, Giliani S, Mellbye OJ, et al. A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency. Clin Exp Immunol. 1997;107:230–4.Google Scholar
  16. 16.
    Djerbi M, Screpanti MV, Catrina AI, et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190:1025–31.PubMedGoogle Scholar
  17. 17.
    French LE, Tshopp J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med. 1999;190:891–3.PubMedGoogle Scholar
  18. 18.
    Medema JP, Jong Jd, Hall Tv, et al. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med. 1999;190:133–8.Google Scholar
  19. 19.
    Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med. 2001;7:94–100.PubMedGoogle Scholar
  20. 20.
    Qin Z, Blankenstein T. Tumor growth inhibition by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Cancer Res. 1995;55:4747–51.PubMedGoogle Scholar
  21. 21.
    Schrama D, Straten PT, Fischer WH, et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001;14:111–21.PubMedGoogle Scholar
  22. 22.
    Latinis KM, Carr LL, Peterson EJ, et al. Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. J Immunol. 1997;158:4602–11.PubMedGoogle Scholar
  23. 23.
    Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Med. 1999;5:90–6.PubMedGoogle Scholar
  24. 24.
    Dao T, Ohashi K, Kayano T, et al. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol. 1996;173:230–5.PubMedGoogle Scholar
  25. 25.
    Fanger NA, Maliszewski CR, Schooley K, et al. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med. 1999;190:1155–64.PubMedGoogle Scholar
  26. 26.
    Griffith TS, Wiley SR, Kubin MZ. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999;189:1343–53.PubMedGoogle Scholar
  27. 27.
    Kayagaki N, Yamaguchi N, Nakayama M, et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med. 1999;189:1451–560.PubMedGoogle Scholar
  28. 28.
    Medvedev AE, Johnsen AC, Haux J, et al. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine. 1997;9:394–404.PubMedGoogle Scholar
  29. 29.
    Smyth MJ, Creteney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193:661–70.PubMedGoogle Scholar
  30. 30.
    Fellenberg J, Mau H, Scheuerpflug C, et al. Modulation of resistance to anti-Apo-1-induced apoptosis in osteosarcoma cells by cytokines. Int J Cancer. 1997;72:536–42.PubMedGoogle Scholar
  31. 31.
    Ossima NK, Cannas A, Powers VC, et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem. 1997;272:16351–7.Google Scholar
  32. 32.
    Lu G, Janjic BM, Janjic J, et al. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, LT-α1β2, FasL and TRAIL. J Immunol. 2002;168:1831–9.PubMedGoogle Scholar
  33. 33.
    Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproeinase disintegrin that releases tumor-necrosis factor-α from cells. Nature. 1997;385:729–33.PubMedGoogle Scholar
  34. 34.
    Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature. 1994;370:555–7.PubMedGoogle Scholar
  35. 35.
    Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777–83.PubMedGoogle Scholar
  36. 36.
    Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-α concerting enzyme. J Biol Chem. 2000;275:14608–14.PubMedGoogle Scholar
  37. 37.
    Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045–50.PubMedGoogle Scholar
  38. 38.
    Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31–6.PubMedGoogle Scholar
  39. 39.
    Kashii Y, Giorda R, Herberman RB, et al. Constitutive expression and role of the TNF family ligands in apoptotic killing by human NK cells. J Immunol. 1999;163:5358–66.PubMedGoogle Scholar
  40. 40.
    Aderka D, Englemann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991;51:5602–7.PubMedGoogle Scholar
  41. 41.
    Gatanaga T, Hwang CD, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA. 1990;87:8781–4.PubMedGoogle Scholar
  42. 42.
    Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor. Tumor Biol. 2005;26:186–94.Google Scholar
  43. 43.
    Shibata M, Takekawa M, Amano S. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today. 1998;28:884–8.PubMedGoogle Scholar
  44. 44.
    Ge L, Baskic D, Basse P, et al. Sheddase activity of tumor necrosis factor-a converting enzyme is increase and prognostically valuable in head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2913–22.PubMedGoogle Scholar
  45. 45.
    Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflamation and tumor cell survival. J Exp Med. 2000;191:1209–19.PubMedGoogle Scholar
  46. 46.
    Wallach D, Varfolmeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331–67.PubMedGoogle Scholar
  47. 47.
    Pasparakis M, Alexopoulou L, Episkopou V, et al. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184:1397–411.PubMedGoogle Scholar
  48. 48.
    Mueller C, Corazza N, Trachsel-Loseth S, et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J Biol Chem. 1999;274:38112–8.PubMedGoogle Scholar
  49. 49.
    Alexopoulou L, Kranidioti K, Xanthoulea S, et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol. 2006;36:2768–80.PubMedGoogle Scholar
  50. 50.
    Canault M, Peiretti F, Mueller C, et al. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis. 2004;172:211–8.PubMedGoogle Scholar
  51. 51.
    Cauwels A, Molle WV, Janssen B, et al. Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity. 2000;13:223–31.PubMedGoogle Scholar
  52. 52.
    Cope AP, Liblau RS, Yang X-D, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185:1573–84.PubMedGoogle Scholar
  53. 53.
    Isomaki P, Panesar M, Annenkov A, et al. Prolonged exposure of T cells to TNF down-regulates TCRζ and expression of the TCR/CD3 complex at the cell surface. J Immunol. 2001;166:5495–507.PubMedGoogle Scholar
  54. 54.
    Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15:533–43.PubMedGoogle Scholar
  55. 55.
    Saunders BM, Tran S, Ruuls S, et al. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol. 2005;174:4852–9.PubMedGoogle Scholar
  56. 56.
    Tanaka M, Suda T, Yatomi T, et al. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol. 1997;158:2303–9.PubMedGoogle Scholar
  57. 57.
    Wajant H, Pfitzenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.PubMedGoogle Scholar
  58. 58.
    Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;128:121–36.Google Scholar
  59. 59.
    Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376.PubMedGoogle Scholar
  60. 60.
    Moretta L, Bottino C, Ferlazzo G. Surface receptors and functional interactions of human natural killer cells: from bench to the clinic. Cell Mol Life Sci. 2003;60:2139–46.PubMedGoogle Scholar
  61. 61.
    Gorelik E, Herberman RB. Role of natural killer (NK) cells in control of tumor growth and metastatic spread. In: Herberman RB, editor. Cancer immunology: inovative approaches to therapy. Boston: Martinus Nijhoff Publishers; 1986. p. 152–76.Google Scholar
  62. 62.
    Gorelik E, Rosen D, Copeland D, et al. Evaluation of the role of natural killer cells in radiation-induced leukemogenesis in mice. J Natl Cancer Inst. 1984;72:1397–403.PubMedGoogle Scholar
  63. 63.
    Ricardi C, Barlozzari T, Santoni A, et al. Transfer of cyclophosphamide-treated mice natural killer (NK) cells and in vivo natural reactivity against tumors. J Immunol. 1981;126:1284–9.Google Scholar
  64. 64.
    Wiltrout RH, Herberman RB, Zhang S-R, et al. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol. 1985;134:4267–75.PubMedGoogle Scholar
  65. 65.
    Vujanovic NL, Nagashima S, Herberman RB, et al. Non-secretory apoptotic killing by human natural killer cells. J Immunol. 1996;157:1117–26.PubMedGoogle Scholar
  66. 66.
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.PubMedGoogle Scholar
  67. 67.
    King PD, Katz DR. Mechanisms of dendritic cell function. Immunol Today. 1990;11:206–11.PubMedGoogle Scholar
  68. 68.
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271–96.PubMedGoogle Scholar
  69. 69.
    Albert ML, Pierce SFA, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359–68.PubMedGoogle Scholar
  70. 70.
    Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–9.PubMedGoogle Scholar
  71. 71.
    Hoffman TK, Meidenbauer N, Dworacki G, et al. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000;60:3542–9.Google Scholar
  72. 72.
    Inaba K, Turley S, Yamaide F, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998;188:2163–73.PubMedGoogle Scholar
  73. 73.
    Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines. J Immunol. 1999;163:130–6.PubMedGoogle Scholar
  74. 74.
    Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423–34.PubMedGoogle Scholar
  75. 75.
    Zitvogel L, Mayordomo JL, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J Exp Med. 1996;183:87–97.PubMedGoogle Scholar
  76. 76.
    Liu S, Yu Y, Zhang M, et al. The involvement of TNF-α-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-β-stimulated human dendritic cells to tumor cells. J Immunol. 2001;166:5407–15.PubMedGoogle Scholar
  77. 77.
    Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo. 1993;7:187–91.PubMedGoogle Scholar
  78. 78.
    Janjic BM, Lu G, Pimenov A, et al. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of a potent apoptosis-inducing pathway. J Immunol. 2002;168:1823–30.PubMedGoogle Scholar
  79. 79.
    Andrews DM, Scalzo AA, Yokoyama WM, et al. Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol. 2003;4:175–81.PubMedGoogle Scholar
  80. 80.
    Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol. 2004;172:1333–9.PubMedGoogle Scholar
  81. 81.
    Ferlazzo G, Tsang ML, Morretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via NKp30 receptor by activated NK cells. J Exp Med. 2002;195:343–51.PubMedGoogle Scholar
  82. 82.
    Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5:405–11.PubMedGoogle Scholar
  83. 83.
    Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327–33.PubMedGoogle Scholar
  84. 84.
    Goodier M, Londei M. Lipopolysaccharide stimulates the proliferation of human CD56+CD3 NK cells: A regulatory role of monocytes and IL-10. J Immunol. 2000;165:139–47.PubMedGoogle Scholar
  85. 85.
    Jinushi M, Takehara T, Kanto T. Critical role of MHC class I-related chain A and B expression on IFN-alpha stimulated dendritic cells in NK cell activation: Impairment in chronic hepatitis C virus infection. J Immunol. 2003;170:1249–56.PubMedGoogle Scholar
  86. 86.
    Kalinski P, Maillard RB, Giermasz A. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005;5:1303–15.PubMedGoogle Scholar
  87. 87.
    Mailliard RB, Son Y-I, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol. 2003;171:2366–73.PubMedGoogle Scholar
  88. 88.
    Moretta A. Natural killer cells and dendritic cells:randezvous in abused tissues. Nat Rev Immunol. 2002;2:957–64.PubMedGoogle Scholar
  89. 89.
    Moretta A, Marcenaro E, Sivori S, et al. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. TRENDS Immunol. 2005;26:668–75.PubMedGoogle Scholar
  90. 90.
    Osada T, Nagawa H, Kitayama J, et al. Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function. Cell Immunol. 2001;213:14–23.PubMedGoogle Scholar
  91. 91.
    Piccioli D, Sbrana S, Melandri E, et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195:335–41.PubMedGoogle Scholar
  92. 92.
    Poggi A, Carosio R, Spaggiari GM, et al. NK cell activation of dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tar C-terminal domain. J Immunol. 2002;168:95–101.PubMedGoogle Scholar
  93. 93.
    Yu Y, Hagihara M, Ando K, et al. Enhancment of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol. 2001;166:1590–600.PubMedGoogle Scholar
  94. 94.
    Carbone E, Terrazzano G, Ruggiero G, et al. Recognition of autologous dendritic cells by human NK cells. Eur J Immunol. 1999;29:4022–9.PubMedGoogle Scholar
  95. 95.
    Chiesa MD, Vitale M, Carlomagno S, et al. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressin CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol. 2003;33:1654–66.Google Scholar
  96. 96.
    Ferlazzo G, Morandi B, D’Agostino A, et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol. 2003;33:306–13.PubMedGoogle Scholar
  97. 97.
    Ferlazzo G, Semino C, Melioli G, et al. HLA class I molecule expression is up-regulated during maturation of dendritic cells, protecting them from natural killer cell-mediated lysis. Immunol Lett. 2001;76:34–41.Google Scholar
  98. 98.
    Geldhof AB, Moser M, Lespagnard L, et al. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood. 1998;91:196–206.PubMedGoogle Scholar
  99. 99.
    Hayakawa Y, Screpanti V, Yagita H, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol. 2004;172:123–9.PubMedGoogle Scholar
  100. 100.
    Spaggiari GM, Carosio R, Pende D, et al. NK cell mediated lysis of autologous antigen presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30a nad NKp46. Eur J Immunol. 2001;3:1656–65.Google Scholar
  101. 101.
    Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. TRENDS Immunol. 2001;22:633–40.PubMedGoogle Scholar
  102. 102.
    Cooper MA, Fehniger TA, Fuchs A. NK cell and DC interactions. TRENDS Immunol. 2004;25:47–52.PubMedGoogle Scholar
  103. 103.
    Vujanovic NL. Testing natural killer cells. In: Lotze MT, Thomson AW, editors. Measuring immunity. New York: Academic Press, Elsevier Science; 2004. p. 396–403.Google Scholar
  104. 104.
    Li S, Xu J, Makarenkova VP, et al. A novel epitope of N-CAM defines precursors of human adherent NK cells. J Leuk Biol. 2004;76:1187–99.Google Scholar
  105. 105.
    Lanier LL, Phillips JH. Natural killer cells. Curr Opin Immunol. 1992;4:38–42.PubMedGoogle Scholar
  106. 106.
    Robertson MJ, Ritz J. Biology and clinical relevance of human NK cells. Blood. 1990;76:2421–38.PubMedGoogle Scholar
  107. 107.
    Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopietic transplants. Science. 2002;295:2097–100.PubMedGoogle Scholar
  108. 108.
    Yokoyama WM, Plougastel BFM. Immune function encoded by the natural killer gene complex. Nature Rev Immunol. 2003;3:304–16.Google Scholar
  109. 109.
    Bramson WY. Role of dendritic cell-derived cytokines in immune regulation. Current Pharm Des. 2001;7:977–92.Google Scholar
  110. 110.
    Stager S, Kaye PM. CD8+ T-cell priming regulated by cytokines of the innate immune system. Trends Mol Med. 2004;10:366–71.PubMedGoogle Scholar
  111. 111.
    Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity. 2003;19:641–4.PubMedGoogle Scholar
  112. 112.
    Borg C, Jalil A, Laderach D, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104:3267–75.PubMedGoogle Scholar
  113. 113.
    Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med. 2004;200:287–95.PubMedGoogle Scholar
  114. 114.
    Rodriguez-Calvillo M, Duarte M, Tirapu I, et al. Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp Hematol. 2002;30:195–204.PubMedGoogle Scholar
  115. 115.
    van den Broeke LT, Daschbach E, Thomas EK, et al. Dendritic cell-induced activation of adaptive and innate immunity. J Immunol. 2003;171:5842–52.PubMedGoogle Scholar
  116. 116.
    Vujanovic L, Szymkowski DE, Vujanovic NL, et al. Virally-infected and cytokine-matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood. 2010;116:575–83.PubMedGoogle Scholar
  117. 117.
    Makarenkova V, Chakrabarti AK, Liberatore JA, et al. Dendritic cells and natural killer cells interact via multiple TNF family molecules. J Leuk Biol. 2005;77:408–13.Google Scholar
  118. 118.
    Xu J, Chakrabarti AK, Tan JA, et al. Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell cross-talk. Blood. 2007;109:3333–41.PubMedGoogle Scholar
  119. 119.
    Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavadge involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5:207–16.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Departments of Pathology and ImmunologyUniversity of PittsburghPittsburghUSA
  2. 2.Hillman Cancer CenterUniversity of PittsburghPittsburghUSA

Personalised recommendations